AbCellera Biologics (NASDAQ:ABCL) Earns Hold Rating from Benchmark

AbCellera Biologics (NASDAQ:ABCLGet Free Report)‘s stock had its “hold” rating reaffirmed by analysts at Benchmark in a research note issued to investors on Monday,Benzinga reports.

A number of other research firms have also recently issued reports on ABCL. Stifel Nicolaus cut their price objective on shares of AbCellera Biologics from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. KeyCorp lowered their target price on shares of AbCellera Biologics from $5.00 to $4.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th.

View Our Latest Report on ABCL

AbCellera Biologics Stock Down 0.8 %

Shares of AbCellera Biologics stock opened at $2.34 on Monday. AbCellera Biologics has a twelve month low of $2.20 and a twelve month high of $5.13. The stock has a market cap of $691.16 million, a price-to-earnings ratio of -3.84 and a beta of 0.42. The company’s fifty day moving average is $3.07 and its 200 day moving average is $2.84.

Institutional Investors Weigh In On AbCellera Biologics

A number of institutional investors and hedge funds have recently made changes to their positions in ABCL. Arcadia Investment Management Corp MI acquired a new stake in shares of AbCellera Biologics in the 3rd quarter worth about $26,000. DKM Wealth Management Inc. purchased a new stake in AbCellera Biologics in the 4th quarter valued at about $29,000. State of New Jersey Common Pension Fund D purchased a new stake in AbCellera Biologics in the 4th quarter valued at about $36,000. Balyasny Asset Management L.P. purchased a new stake in AbCellera Biologics in the 4th quarter valued at about $40,000. Finally, Mariner LLC purchased a new stake in AbCellera Biologics in the 4th quarter valued at about $42,000. Institutional investors and hedge funds own 61.42% of the company’s stock.

AbCellera Biologics Company Profile

(Get Free Report)

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.

Further Reading

Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.